Gonadotropin releasing hormone (GnRH) antagonists suppress follicle-stimulating hormone (FSH) to lower levels than GnRH agonists. This may partially explain the differences between these agents on prostate cancer outcomes. In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist
Boccardo, F;
2018-01-01
Abstract
Gonadotropin releasing hormone (GnRH) antagonists suppress follicle-stimulating hormone (FSH) to lower levels than GnRH agonists. This may partially explain the differences between these agents on prostate cancer outcomes. In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
2.52 MB
Formato
Adobe PDF
|
2.52 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.